Literature DB >> 12373350

Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia.

X Thomas1, Q H Le, D Fiere.   

Abstract

We describe three cases of acute promyelocytic leukemia (APL) with long-term disease-free survival who developed congestive heart failure (CHF) requiring cardiac transplantation. All three patients presented late-onset cardiotoxicity. Cardiac failure occurred progressively after 31-month, 32-month, and 14-month intervals, respectively, following completion of first anthracycline therapy. Cumulative anthracycline doses were 585 mg of daunorubicin and 64 mg of mitoxantrone in case 1, 1779 mg of daunorubicin in case 2, and 825 mg of daunorubicin in case 3. The questions relating to the pathogenesis of cardiac failure are discussed. We also discuss the prophylactic measures required for such treatment-related side effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373350     DOI: 10.1007/s00277-002-0534-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  16 in total

1.  Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis.

Authors:  Zahra Tavakoli Dargani; Dinender K Singla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-07       Impact factor: 4.733

Review 2.  How I treat children and adolescents with acute promyelocytic leukaemia.

Authors:  Oussama Abla; Raul C Ribeiro
Journal:  Br J Haematol       Date:  2013-09-30       Impact factor: 6.998

3.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Authors:  Yasmin Abaza; Hagop Kantarjian; Guillermo Garcia-Manero; Elihu Estey; Gautam Borthakur; Elias Jabbour; Stefan Faderl; Susan O'Brien; William Wierda; Sherry Pierce; Mark Brandt; Deborah McCue; Rajyalakshmi Luthra; Keyur Patel; Steven Kornblau; Tapan Kadia; Naval Daver; Courtney DiNardo; Nitin Jain; Srdan Verstovsek; Alessandra Ferrajoli; Michael Andreeff; Marina Konopleva; Zeev Estrov; Maria Foudray; David McCue; Jorge Cortes; Farhad Ravandi
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

4.  Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

Authors:  Saisudha Koka; Anindita Das; Shu-Guang Zhu; David Durrant; Lei Xi; Rakesh C Kukreja
Journal:  J Pharmacol Exp Ther       Date:  2010-06-11       Impact factor: 4.030

5.  Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.

Authors:  Tino Kurz; Derek Grant; Rolf Gg Andersson; Robertson Towart; Michelandrea De Cesare; Jan Olof G Karlsson
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

6.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Authors:  Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.

Authors:  Mindy Leech; Lawrence Morris; Moishe Stewart; B Douglas Smith; Asad Bashey; Kent Holland; Scott Solomon; Xu Zhang; Hetty E Carraway; Keith Pratz; Steven D Gore; Amer M Zeidan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-11-15

Review 8.  Doxorubicin cardiomyopathy.

Authors:  Kanu Chatterjee; Jianqing Zhang; Norman Honbo; Joel S Karliner
Journal:  Cardiology       Date:  2009-12-11       Impact factor: 1.869

9.  Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.

Authors:  Steven D Gore; Ivana Gojo; Mikkael A Sekeres; Lawrence Morris; Marcel Devetten; Katarzyna Jamieson; Robert L Redner; Robert Arceci; Ibitayo Owoeye; Tianna Dauses; Esther Schachter-Tokarz; Robert E Gallagher
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

Review 10.  Acute promyelocytic leukemia in childhood.

Authors:  John Gregory; James Feusner
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.